Heura Domènech on Muck Rack

Heura Domènech

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Heura

Contact Heura, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program

|
By Sara Marisa Simonetti, Stephen Pettitt, Paula Proszek, Cristina Viaplana, Lorena Magraner-Pardo, Eduardo García-Galea, Carmen Garcia-Duran, Marcel Romey, Sara Arce-Gallego, Anna Suñol, Flaminia Pedretti, Andrea Herencia-Ropero, Paolo Nuciforo, Mafalda Oliveira, Cristina Saura, Isabel Pimentel, Carsten Denkert, Christopher Lord Verified, Andrew Tutt, Aleix Prat, Rodrigo Dientsmann, Susana Aguilar, Sara Gutiérrez-Enríquez, Joaquin Mateo, Ana Oaknin, Judith Balmaña, Alba Llop-Guevara, Ana Vivancos, Violeta Serra, Heura Domènech, Paula Romero-Lozano, Michaela Smalley, Adela Rodríguez-Hernández, Joanna Domènech-Vivó
| Nature Verified
Abstract PARP inhibitors (PARPi) are effective in tumors with homologous recombination repair (HRR) deficiency (HRD), typically identified by germline/tumor mutations. However, genetic testing may miss intrinsic PARPi sensitivity and resistance. We evaluated strategies to improve detection and longitudinal monitoring of HRD across >500 tumor samples and >20 paired liquid biopsies, integrating genetic, genomic, and functional readouts.
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified